Background: Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver oncogene, BCR-ABL1, which is a constitutive tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the central treatment strategy for CML patients and have significantly improved survival rates, but the T315I mutation in the kinase domain of BCR-ABL1 confers resistance to all clinically approved TKIs, except ponatinib. However, compound mutations can mediate resistance even to ponatinib and remain a clinical challenge in CML therapy. Here, we investigated a ponatinib-resistant CML patient through whole-genome sequencing (WGS) to identify the cause of resistance and to find alternative therapeutic targets.
introduction
Chronic myeloid leukaemia (CML) is driven by a constitutive tyrosine kinase, BCR-ABL1, which results from a reciprocal translocation t(9;22)(q34;q11) in haemopoietic stem cells [1] . Tyrosine kinase inhibitors (TKIs) are the main treatment of CML and have improved disease management and survival [2] . However, resistance is a persistent clinical problem and a significant proportion of patients will progress on first-line therapy due to the emergence of TKI-resistant clones. In some patients, TKI resistance is mediated by BCR-ABL1-independent mechanisms, including increased BCL2 expression and overexpression of LYN kinase, but 20%-30% of patients progress due to acquired point mutations in the BCR-ABL1 kinase domain that disrupt TKI binding. In particular, BCR-ABL1 p.T315I (the 'gatekeeper' mutation) confers resistance to all approved firstand second-line TKIs, including imatinib, nilotinib, dasatinib, and bosutinib [3] [4] [5] .
Notably, BCR-ABL1 p.T315I remains sensitive to the TKI ponatinib, a third-line inhibitor [6] . Although an initial response to ponatinib is promising in patients with single mutations in BCR-ABL1, response in advanced patients is limited because successive or long-term use of TKIs lead to the evolution of compound BCR-ABL1 kinase domain mutations that show resistance even to ponatinib [7, 8] . No fourth-line treatments have yet been approved for ponatinib-resistant CML.
We used whole-genome sequencing (WGS) to characterise a ponatinib-resistant CML patient. This revealed a constellation of BCR-ABL1 mutations that were not detected in diagnostic Sanger sequencing approaches. The WGS approach also revealed amplification of the anti-apoptotic gene BCL2 and we show that this patient's CML cells were susceptible to a ponatinib/ABT-263 combination, revealing a therapeutic strategy that may have been effective in this patient.
patients and methods
Detailed experimental procedures are in supplementary Methods, available at Annals of Oncology online. Briefly, tissues were collected following informed consent and ethical approval from the scientific subcommittee of the Manchester Cancer Research Centre Tissue Biobank and in compliance with the ethical and legal framework of the Human Tissue Act, 2004. results
We report on a patient in their 70s who presented with chronic phase CML. The patient was initially treated with imatinib (400 mg/day), which resulted in a complete haematological response (CHR), but failed to achieve a complete cytogenetic response (CCR) at 6 months (Figure 1 A) . Dose escalation of imatinib (600 mg/day), followed by the second-generation TKI dasatinib (100 mg/day), each for 6 months also failed to produce a CCR ( Figure 1A ) and due to nilotinib and interferon intolerance, the patient was again placed on standard-dose imatinib. BCR-ABL1 mutation analysis at this time demonstrated a C>T, p.T315I mutation, but the patient was not considered suitable for allogeneic bone marrow transplantation due to co-morbidities. In the absence of haematological response, imatinib was discontinued and the patient was treated with hydroxycarbamide. Three years following diagnosis, the patient was treated with ponatinib (45 mg/day) and despite achieving a temporary CHR, a CCR was never achieved, and within 9 months the CHR was lost, as revealed by a rising white blood cell count. The patient was retreated with hydroxycarbamide, but developed leg ulceration necessitating discontinuation ( Figure 1A ). The patient remains in chronic phase with disease control being achieved with intermittent etoposide (Bristol-Myers Squibb Pharmaceuticals Limited, Uxbridge). To characterise further the patient's disease, we carried out WGS on CD34 + cells isolated from blood 57 months after diagnosis ( Figure 1A and B) . The CD34 + cells were 99.5% BCR-ABL1 + by FISH, and germline DNA was isolated from buccal epithelial cells ( Figure 1A and B) . We observed 12 466 predicted somatic single-nucleotide variants (SNVs) in the patient's CML cells, resulting in 23 predicted non-synonymous mutations (Table 1) , a modest mutational burden that is similar to that seen in acute myeloid leukaemia (AML), but considerably lower than that in cutaneous melanoma, colorectal adenocarcinoma, and lung cancers, which are associated with known carcinogens (Figure 2A ). Approximately 40% of the somatic mutations were C>T (G>A) transitions and approximately 20% T>C (A>G) transitions ( Figure 2B ), also a common mutation signature in AML [10] . Trinucleotide analysis of the mutant base and its flanking nucleotides ( Figure 2C ) revealed a match to the recently described mutational signature 1B, which is common in several cancers including AML, acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), and B-cell lymphoma [11] .
Among the 23 predicted somatic coding region SNVs, 10 occur at a frequency of <0.05% in the dbSNP database (Table 1 and Figure 3A) . Notably, RNA-seq analysis revealed that only 12 of the 23 predicted SNVs were expressed and of the 4 previously reported in cancers (COSMIC, http://cancer.sanger.ac.uk/ cosmic), only ABL1 (C>T, p.T315I) and ABL1 (T>G, p.F359V) were expressed ( Table 1 ). The ABL1 mutations are also the only missense SNVs that have been reported in CML (COSMIC) and have a damaging effect on protein function as predicted by SIFT and PolyPhen scores (Table 1) . We used a 10% threshold to call the SNVs (supplementary Methods, available at Annals of Oncology online), so to detect lower-frequency SNVs in the ABL1 kinase domain we set the detection limit to 0.1%, but did not detect any additional mutations. However, when we manually scanned this region in the Integrative Genomic Viewer (IGV v2.3.3.38), we observed an additional 53 low-frequency SNVs, but only 2 of these were validated by Sanger sequencing (supplementary Table S1 , available at Annals of Oncology online). To investigate this region further, we carried out PCR-mediated shot-gun cloning and Sanger sequencing of the BCR-ABL1 kinase domain [12] , comparing a pre-ponatinib sample from 21 months to the post-ponatinib sample obtained at 57 months. The p.T315I mutation was present in 100% of the clones from the pre-ponatinib sample and ∼21% of these carried additional point mutations ( Figure 3B ), including p.E225G/T315I and p.T315I/F359C compound mutations (supplementary Table S2 , available at Annals of Oncology online), which have been shown to mediate ponatinib resistance [8] . Intriguingly, following ponatinib treatment, we observed a reduction of p.T315I to ∼17% of the clones, with emergence of a new dominant clone (∼53%) carrying a p. F359V mutation ( Figure 3B ). Moreover, following ponatinib, the number of compound mutations increased to ∼45% and included p.T315I/M351V which also confers ponatinib resistance [8] (supplementary Table S2 , available at Annals of Oncology online).
We predicted 58 loss of heterozygosity (LOH) SNVs in the coding regions, 20 of which have been reported (COSMIC; Figure 3A and supplementary Table S3 , available at Annals of Oncology online). We predicted 183 somatic small insertions or deletions (indels), but none in the coding regions. We also predicted 12 chromosomal translocations with the potential to generate fusion genes, 2 of which were the balanced t(9;22)(q34; q11) reciprocal translocations that create BCR-ABL1 (Figure 3A  and supplementary Table S4 , available at Annals of Oncology online). However, our RNA-seq revealed that only BCR-ABL1 and ABL1-BCR were expressed, strongly suggesting that BCR-ABL1 was the driver oncogene (supplementary Table S4 , available at Annals of Oncology online) and that the other potential fusions were not pathogenic.
We predicted 53 large chromosomal deletions and 7 large chromosomal amplifications ( Figure 3A) . Two of the deletions and three of the amplifications affected coding regions (supplementary Table S5 , available at Annals of Oncology online). A large deletion of 5q23 is similar to that previously described in a blast crisis patient (supplementary Table S5 , available at Annals of Oncology online), but we noted an ∼8 Mb amplification of chromosome 18q that harbours the anti-apoptotic gene BCL2. BCL2 upregulation is associated with sensitivity to BCL2 inhibitors, so we modelled this using two BCR-ABL1 + cell lines, BV173R and K562 cells. BV173R cells expressed approximately seven-fold more BCL2 than K562 cells ( Figure 4A ) and were significantly more sensitive to a BH3-mimetic BCL2 inhibitor, ABT-263 [13] ( Figure 4B ). We confirmed that BCL2 expression was 14-fold higher in the patient's CD34 + CML cells than normal mobilised CD34 + cells ( Figure 4A ), and that the patient's CD34 + cells were more sensitive to ABT-263 ( Figure 4B ). Moreover, ponatinib and ABT-263 cooperated to increase apoptosis in the patient's CD34 + cells ( Figure 4C ). These results were reflected in viability assays. Ponatinib and ABT-263 did not significantly suppress the viability of normal CD34 + cells ( Figure 4D ), but both inhibited growth of the patient's CD34 + cells and they cooperated to suppress the growth of these cells ( Figure 4E ). We also examined ABT-199, a second BCL2 inhibitor [14] . ABT-199 was less potent than ABT-263 at inducing apoptosis in the patient's CD34 + cells (supplementary Figure S1A , available at Annals of Oncology online), but it nevertheless cooperated with ponatinib to enhance apoptosis (supplementary Figure S1B , available at Annals of Oncology online). Next, we examined the differentiation capacity of the patient's CD34 + cells that survived the drug treatments. In CFC assays, only ∼5% of the control colonies were erythroid and ∼95% were granulocytic, but the granulocytic fraction decreased to ∼85% in the presence of ponatinib, to ∼60% in the presence of ABT-263, and to only 24% in the presence of both drugs, a trend that was also observed with ABT-199 (Figure 4F and G; supplementary Figures S1C and S2, available at Annals of Oncology online). Thus, in addition to inducing apoptosis and reducing viability, the ponatinib/ ABT-263 combination selectively reduced production of granulocytic lineage cells, either by inducing lineage-specific apoptosis or differentiation of surviving cells down the erythroid lineage. trinucleotide signature 1B. These mutations are thought to result from spontaneous deamination of 5-methyl-cytosine in germline and normal somatic cells [11] . Although the aetiology of these cells is unclear, this signature is age-related and particularly common in haematological malignancies including ALL, AML, CLL, and B-cell lymphoma [11] , suggesting a common somatic mutation mechanism in these diseases. We observed a modest mutational burden, characteristic of cancers that are not associated with known carcinogens such as ultraviolet light or cigarette smoke. Moreover, the WGS revealed an ABL1 p.F359V mutation that was not detected by diagnostic Sanger sequencing. We confirmed the presence of this mutation by shot-gun cloning and Sanger sequencing, and it is unclear why the diagnostic Sanger sequencing did not reveal this mutation, but one possibility is that the wild-type codon is favoured for base incorporation and thereby masks the mutant allele. The shot-gun sequencing also revealed several compound mutations that were not identified by WGS, because read-length limitations only reveals these when they are within ∼100 bases of each other. Finally, the shot-gun sequencing identified many lowfrequency BCR-ABL1 kinase domain mutations that were not revealed by WGS, possibly because of low read-depth in our WGS or because they are PCR-generated artefacts of the shotgun cloning. These observations highlight why a combination of sequencing approaches is desirable when performing these studies, but these considerations aside, our data suggest that there was dramatic treatment-driven clonal evolution. This presumably accounts for the failure to achieve a CCR despite the initial haematological response and is in agreement with recent data, showing that p.T315I TKI-resistant CML patients fail to respond to ponatinib due to emergence of compound BCR-ABL1 kinase domain mutations [8] . It has also been reported that sequential TKI treatments in relapsed CML patients can drive clonal selection of BCR-ABL1 mutants that were present at a low frequency before treatment commenced [12, 15] .
The reciprocal t(9;22)(q34;q11) translocation is the hallmark of CML [1] . It was predicted by our WGS and RNA-seq results, and validated by our shot-gun cloning approach. The BCR-ABL1 fusion gene in this patient is the e14a2 isoform that occurs between exons 14 and 15 of BCR, generating the BCR-ABL1 p210 fusion protein. The importance of e13a2 and e14a2 isoforms to risk stratification at the time of diagnosis is debated, but it has been suggested that the e14a2-type CML cells can activate HLA-mediated T-cell response that can be exploited in IFN-α therapy [16] .
It is unclear what contribution the large chromosomal structural variations (SVs) made towards the disease. A putative amplification of ∼42 Mb on chromosome 6 harbours 370 genes, C>G  C>T  T>A  T>C  T>G   ACG  ACA  ACC  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACC  ACA  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GCC  GTG  GTT  TTA  TTC  TTG  TTT   80   100 including 16 HLA family genes that modulate T-cell response towards leukaemic cells [16] . This region also includes TNF, which modulates CML CD34 + cell survival, and whose coinhibition with BCR-ABL1 induces CML cell death [17] .
Importantly, we observed a putative ∼8 Mb amplification on chromosome 18 that harbours BCL2, a pro-survival driver oncogene in B-cell lymphomas [18] . BCL2 is important in CML pathogenesis, progression to blast crisis [19, 20] , and its overexpression is associated with TKI resistance [3] . BCL2 inhibitors such as ABT-263 and ABT-199 are in phase 2 clinical trials [14, 21] . We find that the chromosomal SV that leads to BCL2 amplification in this patient was associated with elevated BCL2 expression and sensitivity to ABT-263 as has been reported for B-cell lymphomas and ALL cells harbouring an IGH-BCL2 fusion or trisomy 18 [13] . However, in other reports, only a modest induction in apoptosis was seen with ABT-263 in BCR-ABL1 + CML cells without any effects on stem cell survival or self-renewal capacity [13, 22] . Using cell lines, we show that the response to ABT-263 is correlated to high levels of BCL2 and independent of BCR-ABL1 expression, supporting the conclusion that the response to ABT-263 we observed in the CML patient's CD34 + cells is due to the BCL2 amplification. This observation suggests BCR-ABL-dependent and BCR-ABLindependent mechanisms of resistance in this patient and notably, the patient's CML cells were highly sensitive to combined inhibition of both resistance pathways. Moreover, the cells that survived the combination treatment favoured erythroid over granulocytic lineage differentiation.
Thus, in summary, we describe the first WGS of CML. The patient developed ponatinib-resistant disease and our data suggest that the underlying mechanism was driven by compound BCR-ABL1 kinase domain mutations and BCL2 overexpression. Our study describes an approach to personalised medicine for CML and we provide a proof-of-principle that the integration of WGS and functional studies can identify new combination treatments for patients who have failed even thirdgeneration BCR-ABL1 inhibitors. Unfortunately, in this case, we were unable to translate our findings into patient's benefit because ABT-263 is not currently licensed.
